The latest price target for CytoMed Therapeutics (NASDAQ:GDTC) was reported by Benchmark on October 10, 2024. The analyst firm set a price target for $5.00 expecting GDTC to rise to within 12 months (a possible 112.77% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for CytoMed Therapeutics (NASDAQ:GDTC) was provided by Benchmark, and CytoMed Therapeutics reiterated their speculative buy rating.

There is no last upgrade for CytoMed Therapeutics

There is no last downgrade for CytoMed Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CytoMed Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CytoMed Therapeutics was filed on October 10, 2024 so you should expect the next rating to be made available sometime around October 10, 2025.

While ratings are subjective and will change, the latest CytoMed Therapeutics (GDTC) rating was a reiterated with a price target of $5.00 to $5.00. The current price CytoMed Therapeutics (GDTC) is trading at is $2.35, which is out of the analyst’s predicted range.